Overview

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
Phase:
Phase 3
Details
Lead Sponsor:
Amylyx Pharmaceuticals Inc.